Absci Corp Total Liabilities
Absci Corp total liabilities. Based on the latest financial reports, Absci Corp (ABSI) has total liabilities worth $22.79 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Absci Corp (ABSI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Absci Corp (2019–2025)
Total liabilities of Absci Corp from 2019 to 2025. This chart illustrates how Absci Corp's total liabilities have evolved over time, based on quarterly financial data.
Absci Corp Competitors by Total Liabilities
The table below lists competitors of Absci Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vestjysk Bank A/S
CO:VJBA
|
Denmark | Dkr43.37 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
China | CN¥944.95 Million |
|
Ultragenyx
NASDAQ:RARE
|
USA | $1.55 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs1.96 Billion |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
China | CN¥12.52 Billion |
|
DL E&C Co Ltd
KO:375500
|
Korea | ₩4.43 Trillion |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
India | Rs22.01 Billion |
|
Changzheng Engineering Co Ltd
SHG:603698
|
China | CN¥3.93 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Absci Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Absci Corp assets under control.
Liquidity & Leverage Metrics
Absci Corp Total Liabilities Ratios Explained
Absci Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Absci Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Absci Corp (2019–2025)
The table below shows the annual total liabilities of Absci Corp from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.85 Million | -22.12% |
| 2024-12-31 | $34.48 Million | -16.16% |
| 2023-12-31 | $41.12 Million | -11.74% |
| 2022-12-31 | $46.59 Million | -22.46% |
| 2021-12-31 | $60.09 Million | +178.65% |
| 2020-12-31 | $21.56 Million | -64.43% |
| 2019-12-31 | $60.63 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more